Tram 34

Manufactured by R&D Systems

Sourced in United States

TRAM-34 is a small molecule inhibitor that selectively targets the transient receptor potential (TRP) channel protein TRPM4. It functions by blocking the TRPM4 channel, which is involved in regulating various cellular processes. The core function of TRAM-34 is to serve as a research tool for studying the role of TRPM4 in biological systems.

Automatically generated - may contain errors

Lab products found in correlation

Glial fibrillary acidic protein (gfap), by Agilent Technologies (1 mentions) β actin, by Merck Group (1 mentions) Cs 56, by Merck Group (1 mentions) Recombinant human tgf β, by R&D Systems (1 mentions) Calcein am, by Thermo Fisher Scientific (1 mentions) Maraviroc, by Merck Group (1 mentions) Ici 118 551 hydrochloride, by Merck Group (1 mentions) Infliximab, by Merck Group (1 mentions) Rituximab, by Abcam (1 mentions) Staphylococcal enterotoxin a sea, by Merck Group (1 mentions)

2 protocols using tram 34

TGF-β Signaling Pathway Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human TGF-β and TRAM-34 were purchased from RandD Systems, Inc (Minneapolis, MN, USA). The following primary antibodies were used: phospho-Smad2/Smad2 and phospho-Smad3/Smad3 (12747, Cell Signaling Technology, Danvers, MA); CS-56 (C8035, Sigma-Aldrich; St Louis, MO); β-actin (A5316, Sigma-Aldrich); GFAP (Z0334, Dako, Glostrup, Denmark); KCa3.1 (ab83740, Abcam, USA); Ki67 (ab16667, Abcam, USA).

Yu Z., Yu P., Chen H, & Geller H.M. (2014). Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway. Journal of neurochemistry, 130(1), 41-49.

+ Open protocol

+ Expand

Characterization of Immune Cell Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols

Calcein-AM (#C3100) was purchased from ThermoFisher Scientific, staphylococcal enterotoxin A (SEA, #S9399), Infliximab (#Y0002047), ICI 118,551 hydrochloride (#127-5MG) and Maraviroc (#PZ0002) were from Sigma Aldrich. TRAM 34 (#2946) was purchased from R&D Systems and Venetoclax (ABT-199, #ab217298) from Abcam, Rituximab (lot oN7370B16) was from the local pharmacy (Universitätsklinikum Homburg, Hoffmann La Roche). All other chemicals and reagents not specifically mentioned were from Sigma Aldrich, ThermoFisher Scientific.

Zöphel S., Schwär G., Nazarieh M., Konetzki V., Hoxha C., Meese E., Hoth M., Helms V., Hamed M., & Schwarz E.C. (2020). Identification of molecular candidates which regulate calcium-dependent CD8⁺T-cell cytotoxicity.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!